Triptolide exhibits antitumor effects by reversing hypermethylation of WIF‑1 in lung cancer cells

Mao,Xiaoliang; Tong,Jichun; Wang,Yong; Zhu,Zheng; Yin,Yajun; Wang,Yeming

doi:10.3892/mmr.2018.9263

Triptolide exhibits antitumor effects by reversing hypermethylation of WIF‑1 in lung cancer cells

Authors:
- Xiaoliang Mao
- Jichun Tong
- Yong Wang
- Zheng Zhu
- Yajun Yin
- Yeming Wang
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Changzhou No. 2 People's Hospital, The Affiliated Hospital of Nanjing Medical University, Changzhou, Jiangsu 213000, P.R. China
Published online on: July 9, 2018 https://doi.org/10.3892/mmr.2018.9263
Pages: 3041-3049

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Triptolide (TP) exhibits numerous biological activities, including immunosuppressive, anti‑inflammatory and antitumor effects. The aim of the present study was to investigate the role of TP as a potent therapeutic drug for the treatment of lung cancer and to investigate the underlying therapeutic mechanisms. Western blot analyses and reverse transcription‑quantitative polymerase chain reaction (PCR) were performed to investigate the expression of genes at transcriptional and translational levels, respectively. Methylation‑specific PCR assays were conducted to investigate whether TP affects the Wnt inhibitory factor‑1 (WIF‑1) methylation status and subsequently affects apoptosis, migration or the invasion of lung cancer cells. The results of the present study revealed that the methylation status of WIF‑1 in lung cancer cell lines A549 and H460 was significantly enhanced compared with the human normal bronchial epithelial cell line HBE, whereas treatment with TP was revealed to induce the demethylation of WIF‑1. The present study aimed to investigate whether the biological activities of TP are regulated by inhibiting the Wnt signaling pathway via an increase in WIF‑1 expression levels. The results of the present study revealed that Wnt signaling was suppressed in cells following treatment with TP, which was concluded by the downregulation of Axin 2 and β‑catenin expression. Further investigation demonstrated that the silencing of WIF‑1 expression with small interfering RNA reversed the TP‑induced upregulation of WIF‑1 expression, upregulated Axin 2 and β‑catenin expression and enhanced the activation of Wnt signaling. Notably, an upregulation of cellular tumor antigen p53 expression, and downregulation of matrix metalloproteinase‑9 (MMP‑9) and phosphorylated‑nuclear factor‑κB (NF‑κB) P65 (p‑P65) levels was observed following TP treatment. These results suggest that the Wnt, p53 and NF‑κB signaling pathways mediate the potent antitumor effects of TP. Notably, the silencing of WIF‑1 did not completely recover the levels of p53, MMP‑9 and p‑P65 in cells treated with TP compared with the control cells, thus suggesting that TP exhibits further functions in addition to the targeting of WIF‑1.

View Figures

View References

1	Zhao F, Chen Y, Li R, Liu Y, Wen L and Zhang C: Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. Toxicology. 267:70–79. 2010. View Article : Google Scholar : PubMed/NCBI
2	Borja-Cacho D, Yokoyama Y, Chugh RK, Mujumdar NR, Dudeja V, Clawson KA, Dawra RK, Saluja AK and Vickers SM: TRAIL and triptolide: An effective combination that induces apoptosis in pancreatic cancer cells. J Gastrointest Surg. 14:252–260. 2010. View Article : Google Scholar : PubMed/NCBI
3	Wang W, Li X, Sun W, Zhang L, Zhang M, Hong B and Lv G: Triptolide triggers the apoptosis of pancreatic cancer cells via the downregulation of Decoy receptor 3 expression. J Cancer Res Clin Oncol. 138:1597–1605. 2012. View Article : Google Scholar : PubMed/NCBI
4	Pan J: RNA polymerase-an important molecular target of triptolide in cancer cells. Cancer Lett. 292:149–152. 2010. View Article : Google Scholar : PubMed/NCBI
5	Wu Y, Cui J, Bao X, Chan S, Young DO, Liu D and Shen P: Triptolide attenuates oxidative stress, NF-kappaB activation and multiple cytokine gene expression in murine peritoneal macrophage. Int J Mol Med. 17:141–150. 2006.PubMed/NCBI
6	Jiang XH, Wong BC, Lin MC, Zhu GH, Kung HF, Jiang SH, Yang D and Lam SK: Functional p53 is required for triptolide-induced apoptosis and AP-1 and nuclear factor-kappaB activation in gastric cancer cells. Oncogene. 20:8009–8018. 2001. View Article : Google Scholar : PubMed/NCBI
7	Mackenzie TN, Mujumdar N, Banerjee S, Sangwan V, Sarver A, Vickers S, Subramanian S and Saluja AK: Triptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol Cancer Ther. 12:1266–1275. 2013. View Article : Google Scholar : PubMed/NCBI
8	Gil L and Adonis M: Genomics and proteomics offers new hopes towards a personalized approach to lung cancer prevention and treatment. Elec J Biotechnol. 6:401–409. 2003. View Article : Google Scholar
9	Lemos C, Kathmann I, Giovannetti E, Calhau C, Jansen G and Peters GJ: Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib. Br J Cancer. 100:1120–1127. 2009. View Article : Google Scholar : PubMed/NCBI
10	Sun JM, Won YW, Kim ST, Kim JH, Choi YL, Lee J, Park YH, Ahn JS, Park K and Ahn MJ: The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients. J Cancer Res Clin Oncol. 137:687–694. 2011. View Article : Google Scholar : PubMed/NCBI
11	Rho JK, Choi YJ, Jeon BS, Choi SJ, Cheon GJ, Woo SK, Kim HR, Kim CH, Choi CM and Lee JC: Combined treatment with silibinin and epidermal growth factor receptor tyrosine kinase inhibitors overcomes drug resistance caused by T790M mutation. Mol Cancer Ther. 9:3233–3243. 2010. View Article : Google Scholar : PubMed/NCBI
12	Reya T and Clevers H: Wnt signalling in stem cells and cancer. Nature. 434:843–850. 2005. View Article : Google Scholar : PubMed/NCBI
13	Yamulla RJ, Kane EG, Moody AE, Politi KA, Lock NE, Foley AV and Roberts DM: Testing models of the APC tumor suppressor/β-catenin interaction reshapes our view of the destruction complex in Wnt signaling. Genetics. 197:1285–1302. 2014. View Article : Google Scholar : PubMed/NCBI
14	Logan CY and Nusse R: The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 20:781–810. 2004. View Article : Google Scholar : PubMed/NCBI
15	Sun J and Jin T: Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells. Cell Signal. 20:219–229. 2008. View Article : Google Scholar : PubMed/NCBI
16	Huang C, Ma R, Xu Y, Li N, Li Z, Yue J, Li H, Guo Y and Qi D: Wnt2 promotes non-small cell lung cancer progression by activating WNT/β-catenin pathway. Am J Cancer Res. 5:1032–1046. 2015.PubMed/NCBI
17	Benhaj K, Akcali KC and Ozturk M: Redundant expression of canonical Wnt ligands in human breast cancer cell lines. Oncol Rep. 15:701–707. 2006.PubMed/NCBI
18	Akiri G, Cherian MM, Vijayakumar S, Liu G, Bafico A and Aaronson SA: Wnt pathway aberrations including autocrine Wnt activation occur at high frequency in human non-small-cell lung carcinoma. Oncogene. 28:2163–2172. 2009. View Article : Google Scholar : PubMed/NCBI
19	Uematsu K, He B, You L, Xu Z, McCormick F and Jablons DM: Activation of the Wnt pathway in non small cell lung cancer: Evidence of dishevelled overexpression. Oncogene. 22:7218–7221. 2003. View Article : Google Scholar : PubMed/NCBI
20	Kim J, You L, Xu Z, Kuchenbecker K, Raz D, He B and Jablons D: Wnt inhibitory factor inhibits lung cancer cell growth. J Thorac Cardiovasc Surg. 133:733–737. 2007. View Article : Google Scholar : PubMed/NCBI
21	Ai L, Tao Q, Zhong S, Fields CR, Kim WJ, Lee MW, Cui Y, Brown KD and Robertson KD: Inactivation of Wnt inhibitory factor-1 (WIF1) expression by epigenetic silencing is a common event in breast cancer. Carcinogenesis. 27:1341–1348. 2006. View Article : Google Scholar : PubMed/NCBI
22	Gao Z, Xu Z, Hung MS, Lin YC, Wang T, Gong M, Zhi X, Jablons DM and You L: Procaine and procainamide inhibit the Wnt canonical pathway by promoter demethylation of WIF-1 in lung cancer cells. Oncol Rep. 22:1479–1484. 2009.PubMed/NCBI
23	Lee SM, Park JY and Kim DS: Wif1 hypermethylation as unfavorable prognosis of non-small cell lung cancers with EGFR mutation. Mol Cells. 36:69–73. 2013. View Article : Google Scholar : PubMed/NCBI
24	Tan M, Wu J and Cai Y: Suppression of Wnt signaling by the miR-29 family is mediated by demethylation of WIF-1 in non-small-cell lung cancer. Biochem Biophys Res Commun. 438:673–679. 2013. View Article : Google Scholar : PubMed/NCBI
25	Liu YL, Yang HP, Gong L, Tang CL and Wang HJ: Hypomethylation effects of curcumin, demethoxycurcumin and bisdemethoxycurcumin on WIF-1 promoter in non-small cell lung cancer cell lines. Mol Med Rep. 4:675–679. 2011.PubMed/NCBI
26	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
27	Morita T: Celastrol: A new therapeutic potential of traditional chinese medicine. Am J Hypertens. 23:8212010. View Article : Google Scholar : PubMed/NCBI
28	Ho JN, Byun SS, Lee S, Oh JJ, Hong SK, Lee SE and Yeon JS: Synergistic antitumor effect of triptolide and cisplatin in cisplatin resistant human bladder cancer cells. J Urol. 193:1016–1022. 2015. View Article : Google Scholar : PubMed/NCBI
29	Liu J, Jiang Z, Xiao J, Zhang Y, Lin S, Duan W, Yao J, Liu C, Huang X, Wang T, et al: Effects of triptolide from Tripterygium wilfordii on ERalpha and p53 expression in two human breast cancer cell lines. Phytomedicine. 16:1006–1013. 2009. View Article : Google Scholar : PubMed/NCBI
30	Yao H, Ashihara E and Maekawa T: Targeting the Wnt/β-catenin signaling pathway in human cancers. Expert Opin Ther Targets. 15:873–887. 2011. View Article : Google Scholar : PubMed/NCBI
31	Varela-Nallar L, Grabowski CP, Alfaro IE, Alvarez AR and Inestrosa NC: Role of the Wnt receptor Frizzled-1 in presynaptic differentiation and function. Neural Dev. 4:412009. View Article : Google Scholar : PubMed/NCBI
32	Mazières J, You L, He B, Xu Z, Lee AY and Jablons DM: Wnt Inhibitory Factor 1 (WIF-1) silencing in human non-small cell lung cancer is controlled by promoter hypermethylation. Cancer Res. 65:430. 2005.
33	Liu YL, Yang HP, Zhou XD, Gong L, Tang CL and Wang HJ: The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter, inhibits the canonical Wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr Cancer Drug Targets. 11:1098–1110. 2011. View Article : Google Scholar : PubMed/NCBI
34	Xie J, Zhang Y, Hu X, Lv R, Xiao D, Jiang L and Bao Q: Norcantharidin inhibits Wnt signal pathway via promoter demethylation of WIF-1 in human non-small cell lung cancer. Med Oncol. 32:1452015. View Article : Google Scholar : PubMed/NCBI
35	Esteller M: CpG island hypermethylation and tumor suppressor genes: A booming present, a brighter future. Oncogene. 21:5427–5440. 2002. View Article : Google Scholar : PubMed/NCBI
36	Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M and Esteller M: Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 6:692–702. 2011. View Article : Google Scholar : PubMed/NCBI
37	Li Y, Pan P, Qiao P and Liu R: Downregulation of N-myc downstream regulated gene 1 caused by the methylation of CpG islands of NDRG1 promoter promotes proliferation and invasion of prostate cancer cells. Int J Oncol. 47:1001–1008. 2015. View Article : Google Scholar : PubMed/NCBI
38	He B, You L, Xu Z, Lee A, Reguart N, Rossel R and Jablons D: O-003 Writ inhibitory factor-1 (WIF-1) is silenced by promoter hypermethylation in human non-small cell lung cancer. Lung Cancer. 49:S52005. View Article : Google Scholar
39	Delmas AL, Riggs BM, Pardo CE, Dyer LM, Darst RP, Izumchenko EG, Monroe M, Hakam A, Kladde MP, Siegel EM and Brown KD: WIF1 is a frequent target for epigenetic silencing in squamous cell carcinoma of the cervix. Carcinogenesis. 32:1625–1633. 2011. View Article : Google Scholar : PubMed/NCBI
40	Chan SL, Cui Y, van Hasselt A, Li H, Srivastava G, Jin H, Ng KM, Wang Y, Lee KY, Tsao GS, et al: The tumor suppressor Wnt inhibitory factor 1 is frequently methylated in nasopharyngeal and esophageal carcinomas. Lab Invest. 87:644–650. 2007. View Article : Google Scholar : PubMed/NCBI
41	Bai W, Chen Y and Gao A: Cross talk between poly (ADP-ribose) polymerase 1 methylation and oxidative stress involved in the toxic effect of anatase titanium dioxide nanoparticles. Int J Nanomedicine. 10:5561–5569. 2015.PubMed/NCBI
42	Hodge DR, Peng B, Cherry JC, Hurt EM, Fox SD, Kelley JA, Munroe DJ and Farrar WL: Interleukin 6 supports the maintenance of p53 tumor suppressor gene promoter methylation. Cancer Res. 65:4673–4682. 2005. View Article : Google Scholar : PubMed/NCBI
43	Dai D, Musser JH and Lennox ES: Triptolide derivatives for modulation of apoptosis and immunosuppression. US Patent 7,847,109. Filed May 29, 2003; issued December 7. 2010.
44	Liang M and Fu J: Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett. 270:337–341. 2008. View Article : Google Scholar : PubMed/NCBI
45	Huang W, He T, Chai C, Yang Y, Zheng Y, Zhou P, Qiao X, Zhang B, Liu Z, Wang J, et al: Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS One. 7:e376932012. View Article : Google Scholar : PubMed/NCBI
46	Li L, Kanwar J, Schmitt S, Cui QC, Zhang C, Zhao C and Dou QP: Inhibition of tumor cellular proteasome activity by triptolide extracted from the Chinese medicinal plant ‘thunder god vine’. Anticancer Res. 31:1–10. 2011.PubMed/NCBI
47	Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y and Pan J: Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res. 15:1686–1697. 2009. View Article : Google Scholar : PubMed/NCBI
48	Campbell KJ, Rocha S and Perkins ND: Active repression of antiapoptotic gene expression by RelA (p65) NF-kappa B. Mol Cell. 13:853–865. 2004. View Article : Google Scholar : PubMed/NCBI
49	Lu W, Zhang G, Zhang R, Flores LG II, Huang Q, Gelovani JG and Li C: Tumor site-specific silencing of NF-kappaB p65 by targeted hollow gold nanosphere-mediated photothermal transfection. Cancer Res. 70:3177–3188. 2010. View Article : Google Scholar : PubMed/NCBI
50	Moles A, Butterworth JA, Sanchez A, Hunter JE, Leslie J, Sellier H, Tiniakos D, Cockell SJ, Mann DA, Oakley F and Perkins ND: A RelA (p65) Thr505 phospho-site mutation reveals an important mechanism regulating NF-κB-dependent liver regeneration and cancer. Oncogene. 35:4623–4632. 2016. View Article : Google Scholar : PubMed/NCBI
51	Zhou Y, Hong Y and Huang H: Triptolide attenuates inflammatory response in membranous glomerulo-nephritis rat via downregulation of NF-κB signaling pathway. Kidney Blood Press Res. 41:901–910. 2016. View Article : Google Scholar : PubMed/NCBI
52	Jang BC, Lim KJ, Choi IH, Suh MH, Park JG, Mun KC, Bae JH, Shin DH and Suh SI: Triptolide suppresses interleukin-1beta-induced human beta-defensin-2 mRNA expression through inhibition of transcriptional activation of NF-kappaB in A549 cells. Int J Mol Med. 19:757–763. 2007.PubMed/NCBI
53	Wang X, Zhang L, Duan W, Liu B, Gong P, Ding Y and Wu X: Anti-inflammatory effects of triptolide by inhibiting the NF-κB signalling pathway in LPS-induced acute lung injury in a murine model. Mol Med Rep. 10:447–452. 2014. View Article : Google Scholar : PubMed/NCBI
54	Wang Y, Lu JJ, He L and Yu Q: Triptolide (TPL) inhibits global transcription by inducing proteasome-dependent degradation of RNA polymerase II (Pol II). PLoS One. 6:e239932011. View Article : Google Scholar : PubMed/NCBI
55	Vispé S, Devries L, Créancier L, Besse J, Bréand S, Hobson DJ, Svejstrup JQ, Annereau JP, Cussac D, Dumontet C, et al: Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol Cancer Ther. 8:2780–2790. 2009. View Article : Google Scholar : PubMed/NCBI
56	Carter BZ, Mak DH, Schober WD, Dietrich MF, Pinilla C, Vassilev LT, Reed JC and Andreeff M: Triptolide sensitizes AML cells to TRAIL-induced apoptosis via decrease of XIAP and p53-mediated increase of DR5. Blood. 111:3742–3750. 2008. View Article : Google Scholar : PubMed/NCBI